SCHEMBL11928239

SCHEMBL11928239

C[C@](O)(CN)C(F)(F)F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11928241 1.00
SCHEMBL2371656 1.00
Hydrochloric Acid SCHEMBL2371628 0.97 CYP2D6 (0.35)
Hydrochloric Acid SCHEMBL2373048 0.97 CYP2D6 (0.35)
SCHEMBL12296978 0.81
Cadaverine Tartrate SCHEMBL14783295 0.80 TSHR (0.40)
SCHEMBL3188778 0.77 LMNA (0.33)
SCHEMBL5857345 0.73 ALDH1A1 (0.41)
SCHEMBL2519697 0.73
SCHEMBL16892845 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250361500-A1 (S)-ENGINEERED OXYNITRILASE POLYPEPTIDES AND USES THEREOF NOVARTIS AG (CH) 2025-11-27 US claimed
EP-4536822-A1 (S)-ENGINEERED OXYNITRILASE POLYPEPTIDES AND USES THEREOF Novartis AG (CH) 2025-04-16 EP claimed
US-11911371-B2 Pyridine and pyrazine derivative for the treatment of chronic bronchitis NOVARTIS AG (CH) 2024-02-27 US claimed
US-20240058315-A1 Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis NOVARTIS AG (CH) 2024-02-22 US claimed
WO-2023238078-A1 (S)-ENGINEERED OXYNITRILASE POLYPEPTIDES AND USES THEREOF NOVARTIS AG (CH) 2023-12-14 WO claimed
CN-113891744-A Pyridine and pyrazine derivatives for the treatment of CF, COPD and bronchiectasis 诺华股份有限公司 2022-01-04 CN claimed
US-20210228554-A1 Pyridine and Pyrazine Derivative for the Treatment of CF NOVARTIS AG (CH) 2021-07-29 US claimed
WO-2020250116-A1 PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF, COPD, AND BRONCHIECTASIS NOVARTIS AG (CH) 2020-12-17 WO claimed
US-20200383960-A1 Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis NOVARTIS AG (CH) 2020-12-10 US claimed
US-10117858-B2 Pyridine and pyrazine derivative for the treatment of CF NOVARTIS AG (CH) 2018-11-06 US claimed
US-RE46757-E1 Pyridine and pyrazine derivative for the treatment of CF NOVARTIS AG (CH) 2018-03-20 US claimed
EP-2845593-B1 Pyridine and pyrazine derivative for the treatment of chronic obstructive pulmonary disease NOVARTIS AG (CH) 2017-01-25 EP claimed
US-9365552-B2 Pyridine and pyrazine derivative for the treatment of CF NOVARTIS AG (CH) 2016-06-14 US claimed
EP-2547656-B1 PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF NOVARTIS AG (CH) 2015-09-30 EP claimed
EP-2845593-A1 Pyridine and pyrazine derivative for the treatment of chronic obstructive pulmonary disease Novartis AG (CH) 2015-03-11 EP claimed
US-20150045364-A1 Pyridine and Pyrazine derivative for the Treatment of CF NOVARTIS AG (CH) 2015-02-12 US claimed
WO-2013038373-A1 PYRIDINE AMIDE DERIVATIVES NOVARTIS AG (CH) 2013-03-21 WO claimed
US-8247436-B2 Pyridine and pyrazine derivative for the treatment of CF NOVARTIS AG (CH) 2012-08-21 US claimed
US-20260022366-A1 ENGINEERED NITROALDOLASES CODEXIS INC (US) 2026-01-22 US disclosed
US-20110086847-A1 THIADIAZOLE MODULATORS OF BETA ADRENERGIC RECEPTOR AUSPEX PHARMACEUTICALS, INC. (US) 2011-04-14 US disclosed